乳房显微外科中协同术者的财务影响
回顾性分析2017至2022年264例自体乳房重建,比较协同术者与单人术者病例。协同术者病例住院时间、单侧和双侧手术时间均缩短,总费用、直接费用、间接费用和总收费降低,边际收益增加。作者认为协同术者乳房显微外科不仅提高手术效率,也改善财务指标。
要点
- 协同术者病例住院时间2.4天 vs 单人术者3.1天(P < 0.01)。
- 协同术者单侧手术时间269分钟 vs 370分钟,双侧399分钟 vs 582分钟(均P < 0.01)。
- 协同术者总费用$25,160 vs $31,758,边际收益$1099 vs -$6255(均P < 0.01)。
核心结论
- 协同术者乳房显微外科不仅提高手术效率,也改善财务指标,在向价值医疗模式转变时对提供显微外科乳房重建的医疗系统尤其相关。
研究设计与样本
- 回顾性分析2017年至2022年连续自体乳房重建病例,共264例纳入,其中协同术者117例、单人术者147例。
主要发现
- 协同术者病例住院时间2.4天 vs 单人术者3.1天(P < 0.01)。
- 协同术者单侧手术时间269分钟 vs 370分钟(P < 0.01),双侧399分钟 vs 582分钟(P < 0.01)。
- 协同术者总费用$25,160 vs $31,758(P < 0.01),直接费用$15,558 vs $19,283(P < 0.01),间接费用$9602 vs $12,475(P < 0.01)。
- 协同术者总收费$98,728 vs $120,981(P < 0.01),边际收益$1099 vs -$6255(P < 0.01)。
- 事后分析显示,在所有重建时机分层中纳入协同术者后这些指标均有显著差异,但幅度不同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cosurgeon approaches for autologous breast reconstruction have demonstrated improvements in operative efficiency. The health system financial impact, however, warrants further investigation. METHODS: Retrospective review of consecutive autologous reconstructions was performed between 2017 and 2022. Primary outcome measures consisted of length of stay, operative time, and financial metrics. Cases were stratified by cosurgeon presence, timing, and laterality. RESULTS: A total of 264 cases met inclusion criteria; these consisted of 117 cosurgeon and 147 single-surgeon cases. Cosurgeon cases demonstrated decreased length of stay (2.4 days versus 3.1 days; P < 0.01) and decreased operative time in unilateral (269 minutes versus 370 minutes; P < 0.01) and bilateral (399 minutes versus 582 minutes; P < 0.01) cases. Cosurgeon cases were also associated with decreased total cost ($25,160 versus $31,758; P < 0.01), direct cost ($15,558 versus $19,283; P < 0.01), and indirect cost ($9602 versus $12,475; P < 0.01); decreased total charges ($98,728 versus $120,981; P < 0.01); and increased margin ($1099 versus -$6255; P < 0.01). Post hoc analysis revealed significant differences, albeit at varying magnitudes, in these particular metrics across all levels of reconstruction timing with the inclusion of a cosurgeon. CONCLUSIONS: Cosurgeon breast microsurgery not only improves operative efficiency, but also translates to improved financial metrics. As the transition is made to value-based care models, this is particularly relevant to health systems offering microsurgical breast reconstruction. Analyses of downstream benefits including optimized patient throughput and surgeon opportunity cost warrant investigation.
引用
- DeVito RG, Ke BG, Park RH, et al. The Financial Impact of a Cosurgeon in Breast Microsurgery. Plast Reconstr Surg. 2024. PMID: 39356712. doi:10.1097/PRS.0000000000011791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。